

**Sareum Holdings PLC**

("Sareum" or the "Company")

**Notice of Final Results for the Year Ended 30 June 2024 and Investor Presentation**

**Cambridge, UK, 23 October 2024-** Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, will announce its financial results for the year ended 30 June 2024 on Tuesday, 29 October 2024.

The Company will also be holding a live presentation to investors on Tuesday, 29 October 2024 at 14:30 GMT via the Investor Meet Company platform.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 28 Oct 2024, 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via: <https://www.investormeetcompany.com/sareum-holdings-plc/register-investor>

Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.

A copy of the presentation will be made available on the Company's website following the presentation.

- Ends -

**For further information, please contact:**

**Sareum Holdings plc**

Stephen Parker, Executive Chairman

01223 497700

ir@sareum.co.uk

**Strand Hanson Limited (Nominated Adviser)**

James Dance / James Bellman

020 7409 3494

**Hybridan LLP (Corporate Broker)**

Claire Noyce

020 3764 2341

**ICR Healthcare (Financial PR)**

Jessica Hodgson / Davide Salvi / Kumail Waljee

0203 709 5700

**About Sareum**

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at [www.sareum.com](http://www.sareum.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOREASEAASSLFFA